This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Albireo Pharma Past Earnings Performance

Past criteria checks 0/6

Key information

-18.1%

Earnings growth rate

-3.0%

EPS growth rate

Biotechs Industry Growth	-14.6%
Revenue growth rate	49.3%
Return on equity	-131.1%
Net Margin	-228.5%
Last Earnings Update	30 Sep 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Albireo Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:BDQM Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 22	57	-131	80	87
30 Jun 22	51	-36	77	85
31 Mar 22	45	-33	72	83
31 Dec 21	41	-34	71	81
30 Sep 21	11	-48	65	81
30 Jun 21	9	-136	59	82
31 Mar 21	9	-120	51	79
31 Dec 20	8	-108	44	76
30 Sep 20	12	-90	35	70
30 Jun 20	11	-82	30	60
31 Mar 20	11	-78	27	53
31 Dec 19	10	-63	24	45
30 Sep 19	4	-71	23	41
30 Jun 19	3	-63	21	38
31 Mar 19	2	-61	20	34
31 Dec 18	13	-46	18	31
30 Sep 18	12	-35	17	26
30 Jun 18	12	-28	17	19
31 Mar 18	11	-19	17	16
31 Dec 17	0	-24	16	13
30 Sep 17	3	-31	16	10
30 Jun 17	3	-28	13	9
31 Mar 17	11	-20	12	9
31 Dec 16	11	-16	10	8
30 Sep 16	13	-5	8	8
30 Jun 16	13	-4	8	7
31 Mar 16	5	-8	5	6

Quality Earnings: BDQM is currently unprofitable.

Growing Profit Margin: BDQM is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BDQM is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.

Accelerating Growth: Unable to compare BDQM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BDQM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7%).

Return on Equity

High ROE: BDQM has a negative Return on Equity (-131.05%), as it is currently unprofitable.

This company listing is no longer active

Albireo Pharma Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Third quarter 2022 earnings released: US$1.92 loss per share (vs US$2.96 profit in 3Q 2021)

Albireo Pharma, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$2.04 loss per share (vs US$1.90 loss in 2Q 2021)

Albireo Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

First quarter 2022 earnings released: US$2.19 loss per share (vs US$2.29 loss in 1Q 2021)

Albireo Pharma, Inc. to Report Q1, 2022 Results on May 16, 2022

Recent updates

Forecast to breakeven in 2025

Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $910 million.

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $910 million.

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Albireo Pharma, Inc. Submits Bylvay(R) Alagille Syndrome Regulatory Filings to FDA and EMA

Albireo Pharma, Inc. Appoints Paul Streck as Chief Medical Officer and Craig Hopkinson to its Board of Directors

Third quarter 2022 earnings released: US$1.92 loss per share (vs US$2.96 profit in 3Q 2021)

Albireo Pharma, Inc. Presents New Data at the American Association for the Study of Liver Diseases

Albireo Pharma, Inc. Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia

Albireo Pharma, Inc. to Present Late Breaking Bylvay (odevixibat) Data at AASLD 2022

Albireo Pharma, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Albireo Pharma, Inc. Reports Positive Topline Data from Phase 3 Trial of Bylvay® (Odevixibat) in Alagille Syndrome

Albireo to Showcase New Data at AASLD The Liver Meeting® 2022

No longer forecast to breakeven

Albireo Pharma, Inc. Announces Enabled Reimbursed Access to Bylvay for the Treatment of All Types of Progressive Familial Intrahepatic Cholestasis Patients in Italy

Albireo Pharma, Inc. Announces New Committee Member Appointments

Second quarter 2022 earnings released: US$2.04 loss per share (vs US$1.90 loss in 2Q 2021)

No longer forecast to breakeven

Albireo Pharma, Inc. Announces the Appointments of Habib Dable and Susan Alesina to its Board of Directors

Albireo Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Albireo Pharma, Inc. Announces Lancet Gastroenterology & Hepatology Published the Results of the Pivotal PEDFIC 1 Trial

Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from Russell Microcap Value Index

Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress

Albireo Pharma, Inc. Announces Presentation of New Data in Pediatric and Adult Liver Diseases

Albireo Pharma, Inc. Provides Sales Guidance for the Year 2022

First quarter 2022 earnings released: US$2.19 loss per share (vs US$2.29 loss in 1Q 2021)

Albireo Pharma, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Albireo Pharma, Inc., Annual General Meeting, Jun 16, 2022

Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Albireo Pharma, Inc. Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare and Devastating Children’s Liver Disease

Forecast to breakeven in 2024

Albireo Announces Positive Topline Data from Phase 1 Study of A3907

Albireo Pharma, Inc. Presenting New Bylvay™ (Odevixibat) Data at NASPGHAN 2021

Third quarter 2021 earnings released: EPS US$2.96 (vs US$1.96 loss in 3Q 2020)

Albireo Pharma, Inc. Receives UK MHRA Approval of Bylvay® (odevixibat)

Second quarter 2021 earnings released: US$1.90 loss per share (vs US$1.38 loss in 2Q 2020)

Albireo Pharma, Inc. Announces European Commission Authorization of Bylvay (Odevixibat), the First Drug Approved for the Treatment of All Subtypes of Progressive Familial Intrahepatic Cholestasis

Albireo Pharma, Inc. Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming Easl International Liver Congress

Albireo Pharma, Inc Presents Clinical Data from Its Phase 3 Pedfic 1 Study and an Interim Data Cut of the Pedfic 2 Long-Term Extension Study of Its Lead Product Candidate, Bylvay

Albireo Receives Positive CHMP Opinion for Bylvay™ (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Albireo Pharma, Inc. Announces the Presentation of New Data from its Phase 3 PEDFIC 1 Study and PEDFIC 2 Long-Term Extension Study of its Lead Product Candidate, Bylvay

First quarter 2021 earnings released: US$2.29 loss per share (vs US$2.23 loss in 1Q 2020)

New 90-day low: €27.62

Full year 2020 earnings released: US$6.73 loss per share (vs US$5.04 loss in FY 2019)

Revenue beats expectations

Albireo Pharma, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €34.76

Albireo Announces U.S. Fda Acceptance of New Drug Application for Odevixibat

Albireo Pharma, Inc. Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome

New 90-day high: €33.98

Albireo Pharma, Inc. Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC

Albireo Pharma, Inc. Announce New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease

Third quarter 2020 earnings released: US$1.96 loss per share

Revenue beats expectations

Albireo Pharma, Inc.’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers

Albireo Pharma, Inc. to Report Q3, 2019 Results on Nov 06, 2019

Albireo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $160 million.

New 90-day high - €33.14

New 90-day low - €20.02

Albireo Pharma, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity